By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems has filed for the potential sale of more than 112 million shares of its common stock by its stockholders.

In a Form S-1 filed with the US Securities and Exchange Commission on Tuesday, WaferGen said it will not receive proceeds from the offering, but will receive $34.8 million if warrants included in the offering are exercised in full. Those funds would be used for working capital and general corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.